CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06959641
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:42.624225+00:00
Published At: 2025-06-11T00:00:00+00:00
Record Updated At: 2025-06-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Locally Advanced Differentiated Thyroid Gland Carcinoma", "Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma", "Locally Advanced Thyroid Gland Follicular Carcinoma", "Locally Advanced Thyroid Gland Oncocytic Carcinoma", "Locally Advanced Thyroid Gland Papillary Carcinoma", "Metastatic Differentiated Thyroid Gland Carcinoma", "Metastatic Poorly Differentiated Thyroid Gland Carcinoma", "Metastatic Thyroid Gland Follicular Carcinoma", "Metastatic Thyroid Gland Oncocytic Carcinoma", "Metastatic Thyroid Gland Papillary Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Refractory Poorly Differentiated Thyroid Gland Carcinoma", "Refractory Thyroid Gland Follicular Carcinoma", "Refractory Thyroid Gland Oncocytic Carcinoma", "Refractory Thyroid Gland Papillary Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Thyroid Gland Follicular Carcinoma AJCC v8", "Stage III Thyroid Gland Papillary Carcinoma AJCC v8", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v8", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-11"
protocolSection.identificationModule.nctId: "NCT06959641"
protocolSection.identificationModule.officialTitle: "A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Study condition terms

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.